Compare EOS & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EOS | PRCT |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2004 | 2021 |
| Metric | EOS | PRCT |
|---|---|---|
| Price | $19.78 | $20.79 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $22.25 |
| AVG Volume (30 Days) | 147.5K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | N/A | $28.32 |
| Revenue Next Year | N/A | $20.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $19.44 | $16.67 |
| 52 Week High | $23.62 | $38.11 |
| Indicator | EOS | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 33.55 | 56.53 |
| Support Level | $19.44 | $19.87 |
| Resistance Level | $21.69 | $23.32 |
| Average True Range (ATR) | 0.29 | 1.35 |
| MACD | -0.08 | 0.18 |
| Stochastic Oscillator | 10.07 | 42.10 |
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.